Amgen's $10B Onyx Deal Gets Antitrust Approval
The waiting period under the Hart-Scott-Rodino antitrust law was set to expire next week, but the Federal Trade Commission cut their review short. Amgen and Onyx have few overlapping areas of research, and Onyx has just one proprietary drug on the market, so antitrust risk was seen to be low.
With approvals in hand, Amgen...
To view the full article, register now.